Skip to main content Skip to section navigation Skip to footer

XORTX Therapeutics Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Advisory Board
  • Pipeline
    • Overview
    • XRx-008 for Autosomal Dominant Polycystic Kidney Disease
    • XRx-101 for Coronavirus/COVID-19
    • XRX-225 for Type 2 Diabetic Nephropathy
    • Publications
  • Technology
  • News
    • Press Releases
    • Events
  • Investors
    • Overview
    • News & Events
    • Presentations
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • SEDAR
    • Governance
  • Contact

Press Releases

News

News

  • Press Releases
  • Events
Jun 30, 2021 7:00am EDT

Dr. Stephen Haworth Joins XORTX Management Team

Jun 17, 2021 7:00am EDT

XORTX Welcomes Jaqueline Le Saux to Board of Directors

May 13, 2021 7:00am EDT

XORTX Welcomes New Member to Board of Directors

Apr 06, 2021 7:00am EDT

XORTX Announces Notice to Grant European Patent

Mar 16, 2021 7:00am EDT

XORTX to Present at “Zoom With LD MICRO”

Mar 09, 2021 8:35am EST

XORTX to Present and Participate in the Sachs 14th Annual European Life Sciences CEO Forum 2021

Mar 08, 2021 9:45am EST

XORTX Files New Provisional Patent to Treat and Protect Individuals Most at Risk to Severe Viral Infection

Mar 02, 2021 7:00am EST

XORTX Confirms $1 Million in Warrant Exercise Proceeds

Mar 01, 2021 7:00am EST

XORTX Participating in WuXI Healthcare Forum

Feb 17, 2021 11:35am EST

XORTX to Present at BIO CEO and Investor Conference; Strategies to Decrease Acute and Chronic Kidney Injury, Co-morbidity and Mortality

  • arrow_back
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • arrow_forward
rss_feed News RSS
©2022 XORTX Therapeutics Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap